Introduction

Hepatobiliary cancer (HBC) consists of primary liver malignancies including hepatocellular carcinoma (HCC), gallbladder cancer (GBC), as well as cholangiocarcinoma (1-3). In the United States (US), the incidence of HCC and biliary tract cancers has been steadily increasing due to the high prevalence of chronic hepatitis and the epidemic of nonalcoholic fatty liver disease (4). In fact, according to a Surveillance, Epidemiology, and End Results (SEER) analysis, there were an estimated 50,650 new cases of HBC in 2016 resulting in 30,880 deaths (5). Although surgery can be potentially curative for patients with early stage disease,
patients with advanced HBC disease generally have a dismal prognosis with an expected survival of less than 1 year (6,7). In addition, treatment options are often limited for patients with unresectable or recurrent HBC disease. Specifically, gemcitabine, cisplatin, and sorafenib, an oral tyrosine kinase inhibitor, are the agents most often employed in the setting of advanced HBC disease (7).

Given the current limited options in the treatment of advanced HBC, immunotherapy has been considered a promising treatment option, especially for advanced cancers not amenable to surgical resection (8). Immunotherapy has demonstrated efficacy in the treatment of cancers such as hematological malignancies, melanoma, and lung cancer in several phase III trials (9). In 2011 the Federal Drug Administration (FDA) approved ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody, while in 2014–2015 nivolumab, a programmed death 1 (PD-1) inhibitor, was approved as a new immunotherapy application in patients with advanced HBC (10,11). In turn, an increasing number of clinical trials are currently evaluating the efficacy of different immunotherapeutic regimens in the treatment of advanced HBC (12-14). Overall utilization of immunotherapy among patients diagnosed with HBC has not been previously defined, however. In addition, the characteristics and factors associated with receipt of immunotherapy among HBC patients have not been examined. As such, the objective of the current study was to assess the nationwide utilization of immunotherapy in the treatment of HBC, as well as examine socioeconomic and disease-related factors that might be associated with the receipt of immunotherapy among patients treated for HBC in the US.

Methods

Study population and data collection

Patients who had a diagnosis of HCC, ICC, GBC, or extrahepatic bile duct cancer between January 1, 2004 and December 31, 2015 were identified from the National Cancer Database (NCDB) and were included in the current study. Patients with unknown immunotherapy and/or surgery status were excluded from the analytic cohort. Furthermore, patients with premalignant lesions, neuroendocrine neoplasms, mesenchymal tumors, secondary tumors or American Joint Committee on Cancer (AJCC) clinical Stage 0 tumors were also excluded.

The NCDB is a joint venture of the American College of Surgeons and the American Cancer Society. The NCDB consists of 34 million records collected from 1,500 hospitals nationally that represents 70% of the new oncology cases in the US. The NCDB provides data on demographic characteristics such as age, sex, race, insurance status, income, as well as facility location and type. The NCDB also provides information such as the Charlson-Deyo comorbidity score (CCS), tumor grade, clinical stage, as well as treatment modalities such as chemotherapy, radiation, surgery, and immunotherapy. Patients were identified using the appropriate International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) codes for histology and primary site (Table S1).

Results

Characteristics of patients who received immunotherapy

Among the 249,913 patients diagnosed with HBC who met inclusion criteria, only a minority received immunotherapy (n=585, 0.2%) (Table 1) (Figure 1). Among patients who received immunotherapy, most patients were Caucasian (n=427, 73.0%), had a CCS of 0 (n=364, 62.2%), were diagnosed between 2012 and 2015 (n=272, 46.5%), as well as had private insurance (n=273, 46.7%) and an income ≥$46,000 (n=242, 41.4%). In addition, most patients who received immunotherapy were treated at an academic facility (n=319, 54.5%). The use of immunotherapy among HBC patients varied by diagnosis (HCC n=396, 67.7%; bile duct cancer n=82, 14.0%). The proportion of stage...
Table 1 Demographics and characteristics stratified by the utilization of immunotherapy

<table>
<thead>
<tr>
<th>Variable</th>
<th>Immunotherapy, N=585 (0.2%), n (%)</th>
<th>No immunotherapy, N=249,328 (99.8%), n (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median [IQR]</td>
<td>61 [53–69]</td>
<td>65 [57–75]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male</td>
<td>415 (70.9)</td>
<td>160,695 (64.5)</td>
<td>0.001</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td>0.009</td>
</tr>
<tr>
<td>Caucasian</td>
<td>427 (73.0)</td>
<td>192,663 (77.3)</td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>82 (14.0)</td>
<td>33,091 (13.3)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>76 (13.0)</td>
<td>23,574 (9.5)</td>
<td></td>
</tr>
<tr>
<td>Charlson-Deyo comorbidity index</td>
<td></td>
<td></td>
<td>0.009</td>
</tr>
<tr>
<td>0</td>
<td>364 (62.2)</td>
<td>138,358 (55.5)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>123 (21.0)</td>
<td>62,447 (25.0)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>49 (8.4)</td>
<td>21,892 (8.8)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>49 (8.4)</td>
<td>26,631 (10.7)</td>
<td></td>
</tr>
<tr>
<td>Period of diagnosis</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>2004–2007</td>
<td>193 (33.0)</td>
<td>58,821 (23.6)</td>
<td></td>
</tr>
<tr>
<td>2008–2011</td>
<td>120 (20.5)</td>
<td>83,111 (33.3)</td>
<td></td>
</tr>
<tr>
<td>2012–2015</td>
<td>272 (46.5)</td>
<td>107,396 (43.1)</td>
<td></td>
</tr>
<tr>
<td>Insurance status</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Not insured</td>
<td>22 (3.8)</td>
<td>12,209 (4.9)</td>
<td></td>
</tr>
<tr>
<td>Private insurance</td>
<td>273 (46.7)</td>
<td>77,390 (31.0)</td>
<td></td>
</tr>
<tr>
<td>Medicaid</td>
<td>59 (10.1)</td>
<td>27,183 (10.9)</td>
<td></td>
</tr>
<tr>
<td>Medicare</td>
<td>210 (35.9)</td>
<td>123,831 (49.7)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>21 (3.6)</td>
<td>8,715 (3.5)</td>
<td></td>
</tr>
<tr>
<td>Median income</td>
<td></td>
<td></td>
<td>0.006</td>
</tr>
<tr>
<td>&lt;$30,000</td>
<td>79 (13.5)</td>
<td>40,234 (16.1)</td>
<td></td>
</tr>
<tr>
<td>$30,000–$35,999</td>
<td>86 (14.7)</td>
<td>44,967 (18.0)</td>
<td></td>
</tr>
<tr>
<td>$36,000–$45,999</td>
<td>157 (26.8)</td>
<td>66,947 (26.9)</td>
<td></td>
</tr>
<tr>
<td>≥$46,000</td>
<td>242 (41.4)</td>
<td>87,625 (35.1)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>21 (3.6)</td>
<td>9,555 (3.8)</td>
<td></td>
</tr>
<tr>
<td>Facility type</td>
<td></td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td>Community Cancer Program</td>
<td>35 (6.0)</td>
<td>15,378 (6.2)</td>
<td></td>
</tr>
<tr>
<td>Comprehensive Community Cancer Program</td>
<td>153 (26.2)</td>
<td>77,799 (31.2)</td>
<td></td>
</tr>
<tr>
<td>Academic/Research Program</td>
<td>319 (54.5)</td>
<td>126,262 (50.6)</td>
<td></td>
</tr>
<tr>
<td>Integrated Network Cancer Program</td>
<td>49 (8.4)</td>
<td>26,233 (10.5)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>29 (5.0)</td>
<td>3656 (1.5)</td>
<td></td>
</tr>
<tr>
<td>Facility location</td>
<td></td>
<td></td>
<td>0.002</td>
</tr>
<tr>
<td>Northeast</td>
<td>138 (23.6)</td>
<td>53,258 (21.4)</td>
<td></td>
</tr>
<tr>
<td>Southeast</td>
<td>196 (33.5)</td>
<td>91,182 (36.6)</td>
<td></td>
</tr>
<tr>
<td>Midwest</td>
<td>95 (16.2)</td>
<td>55,090 (22.1)</td>
<td></td>
</tr>
<tr>
<td>West</td>
<td>127 (21.7)</td>
<td>46,142 (18.5)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>29 (5.0)</td>
<td>3,656 (1.5)</td>
<td></td>
</tr>
</tbody>
</table>

Table 1 (continued)
### Table 1 (continued)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Immunotherapy, N=585 (0.2%), n (%)</th>
<th>No immunotherapy, N=249,328 (99.8%), n (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residential setting</td>
<td></td>
<td></td>
<td>0.42</td>
</tr>
<tr>
<td>Rural</td>
<td>5 (0.9)</td>
<td>3,672 (1.5)</td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>69 (11.8)</td>
<td>30,336 (12.2)</td>
<td></td>
</tr>
<tr>
<td>Metro</td>
<td>494 (84.4)</td>
<td>206,321 (82.8)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>17 (2.9)</td>
<td>8,999 (3.6)</td>
<td></td>
</tr>
<tr>
<td>Primary tumor</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>396 (67.7)</td>
<td>147,809 (59.3)</td>
<td></td>
</tr>
<tr>
<td>Intrahepatic cholangiocarcinoma</td>
<td>80 (13.7)</td>
<td>31,328 (12.6)</td>
<td></td>
</tr>
<tr>
<td>Gallbladder cancer</td>
<td>27 (4.6)</td>
<td>25,907 (10.4)</td>
<td></td>
</tr>
<tr>
<td>Extrahepatic bile duct cancer</td>
<td>82 (14.0)</td>
<td>44,284 (17.8)</td>
<td></td>
</tr>
<tr>
<td>Histological confirmation</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No</td>
<td>135 (23.1)</td>
<td>75,283 (30.2)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>450 (76.9)</td>
<td>174,045 (69.8)</td>
<td></td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
<td>0.08</td>
</tr>
<tr>
<td>Well</td>
<td>54 (9.2)</td>
<td>26,093 (10.5)</td>
<td></td>
</tr>
<tr>
<td>Mod</td>
<td>146 (25.0)</td>
<td>51,410 (20.6)</td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>87 (14.9)</td>
<td>35,003 (14)</td>
<td></td>
</tr>
<tr>
<td>Anaplastic</td>
<td>3 (0.5)</td>
<td>1,649 (0.7)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>295 (50.4)</td>
<td>135,173 (54.2)</td>
<td></td>
</tr>
<tr>
<td>AJCC clinical stage</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>I</td>
<td>77 (13.2)</td>
<td>55,458 (22.2)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>68 (11.6)</td>
<td>36,526 (14.6)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>121 (20.7)</td>
<td>36,830 (14.8)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>198 (33.8)</td>
<td>49,132 (19.7)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>121 (20.7)</td>
<td>71,382 (28.6)</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td></td>
<td>0.002</td>
</tr>
<tr>
<td>No</td>
<td>427 (73.0)</td>
<td>166,329 (66.7)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>158 (27.0)</td>
<td>82,999 (33.3)</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No</td>
<td>176 (30.1)</td>
<td>147,628 (59.2)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>408 (69.7)</td>
<td>99,983 (40.1)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>1 (0.2)</td>
<td>1,717 (0.7)</td>
<td></td>
</tr>
<tr>
<td>Radiation</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No</td>
<td>456 (77.9)</td>
<td>216,377 (86.8)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>127 (21.7)</td>
<td>30,217 (12.1)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>2 (0.3)</td>
<td>2,734 (1.1)</td>
<td></td>
</tr>
</tbody>
</table>

IQR, interquartile range; well, well differentiated; mod, moderately differentiated; poor, poorly differentiated.
III and IV disease was also higher among patients who did versus did not receive immunotherapy (54.5% vs. 34.5%, respectively; P<0.001). Most HBC patients who received immunotherapy had also received traditional cytotoxic chemotherapy (n=408, 69.7%), whereas a smaller number of patients had undergone radiation therapy (n=127, 21.7%) or had surgical resection (n=158, 27%). Among non-surgical patients, a biphasic trend was observed with regard to overall immunotherapy utilization; specifically, over the years examined there was a decline in immunotherapy utilization until 2011 with a subsequent increase after 2012 peaking in 2015. In contrast, the utilization of immunotherapy among patients who had surgical resection for HBC steadily decreased over time (Figure 2).

**Pathological characteristics after surgery relative to the timing of immunotherapy**

Among the 136 patients who received surgery and immunotherapy and had available data on the timing of immunotherapy relative to the surgical episode, 31 (22.8%) patients received neoadjuvant immunotherapy and 105 (77.2%) received adjuvant immunotherapy (Table 2). The vast majority of patients with neoadjuvant immunotherapy had a diagnosis of HCC (n=26, 83.9%). Similarly, most patients who received adjuvant immunotherapy had HCC (n=51, 48.6%), followed by extrahepatic bile duct cancer (n=34, 32.4%). Among surgical patients receiving immunotherapy, 17 (12.5%) had N1/N2 disease and 13 (9.6%) had M1 disease. Most patients who received neoadjuvant (n=22, 71.0%) and adjuvant immunotherapy (65, 61.9%) had an R0 margin resection.

**Timing and factors associated with immunotherapy receipt**

Distribution plots with the y-axis defined as the probability density function for the kernel density estimation associated with receipt of immunotherapy were examined. Specifically, the timing of immunotherapy receipt among patients treated for HBC was graphically displayed based on the number of days from diagnosis to receipt of immunotherapy among surgical and non-surgical patients. Among patients who underwent surgical resection for HBC, immunotherapy was more likely to be administered at a mean 96.8 days after diagnosis (post-surgery, mean 50.6 days; post-
cytotoxic chemotherapy, mean 76.8 days; post-radiation, mean 108.1 days) (Figure 3A). Among patients who did not undergo a surgical procedure for HBC, immunotherapy was administered a mean of 73.1 days from diagnosis (post-cytotoxic chemotherapy, mean 54.5 days; post-radiation, mean 74.7 days) (Figure 3B).

Among the 427 patients who received immunotherapy and did not undergo surgery, 257 patients also had another type of systemic chemotherapy [prior immunotherapy n=30 (11.7%), concurrent with other chemotherapy n=131 (51.0%), and after other chemotherapy n=96 (37.3%)].

On multivariable analysis, several socioeconomic and clinical factors were associated with the receipt of immunotherapy (Table 3). In particular, younger patient age [referent <65 years: ≥65 years, odds ratio (OR) 0.69, 95% confidence interval (CI): 0.58–0.82], a more recent period of diagnosis (referent 2008–2011: 2012–2015, OR 1.80, 95% CI: 1.44–2.25), median income ≥$46,000 (referent <$30,000: OR 1.43, 95% CI: 1.11–1.87), diagnosis of HCC (referent: GBC, OR: 2.54, 95% CI: 1.70–3.79), ICC (OR: 1.97, 95% CI: 1.26–3.08) and extrahepatic bile duct cancer (OR: 1.68, 95% CI: 1.08–2.61), higher tumor stage (referent stage I: stage III, OR 2.22, 95% CI: 1.65–3.01; stage IV, OR 3.24, 95% CI: 2.41–4.34) and prior receipt of cytotoxic chemotherapy (OR 3.36, 95% CI: 2.79–4.04) were associated with a higher likelihood of receiving immunotherapy.
imunotherapy. Other variables such as gender, insurance status, facility type, residential setting, tumor grade, as well as history of surgical resection or radiation therapy were not associated with the odds of receiving immunotherapy.

**Discussion**

Recent data have suggested that chronic inflammation may contribute to the risk of developing certain solid tumors types (15). HBC, especially HCC, have been associated with chronic inflammation such as viral hepatitis and nonalcoholic or alcoholic steatohepatitis (16). The oncogenesis of HBC in this setting creates a unique 'tumor microenvironment' that leads to increased immune evasion and T-cell exhaustion (17). In fact, HCC has been reported to demonstrate high levels of PD-1 expression and immunosuppressive cytokines, suggesting that immunotherapeutic approaches may be useful in the treatment of HBC (15,17-20). While progress has been made in immune-based approaches in the treatment of various other malignancies including melanoma, non-small cell lung cancer (NSCLC), renal and bladder cancer (21-24), immunotherapy has only recently been considered as a therapeutic option for patients with advanced HBC (16). The utilization of immunotherapy has not been studied and data on use of immunotherapy among patients with HBC in the US remain largely unknown. The current study was important because we assessed the overall utilization of immunotherapy among HBC patients, examined temporal trends in the utilization, as well as defined the factors associated with receipt of immunotherapy. Of note, only a very small minority (0.2%) of patients received immunotherapy for HBC with the most common indication being HCC. Perhaps not surprisingly, the majority of patients who received immunotherapy were not surgical candidates (73%), had stage III and IV disease (54.5%) at the time of presentation, and most patients received immunotherapy late in the course of their disease. While receipt of immunotherapy was not associated with insurance status, it was associated with median income and a more recent period of diagnosis.

Several clinical trials are currently evaluating the efficacy of different immunotherapeutic regimens in HBC, including peptide-based vaccines, dendritic cell (DC)-based vaccines and antibodies (25). One phase I/II trial (CheckMate 040) demonstrated that the PD-1 inhibitor nivolumab had an acceptable safety profile and promising efficacy among patients with advanced HCC (26). Based on the results of this trial, the FDA approved nivolumab for the treatment of patients with advanced or metastatic HCC who have previously been treated with sorafenib (16,26). As such, it was not surprising in the current study that most patients who received immunotherapy had a diagnosis of HCC relative to other cancers such as gallbladder or cholangiocarcinoma. However, as the indications for immunotherapy for HBC expand, the number of cancer immunotherapy trials listed on the US National Institutes of Health trial registry for all HBC tumor types has progressively increased over the years (27). While the overall use of immunotherapy was very low in the years examined, we did demonstrate an increased trend in the use of immunotherapy over time especially among patients who were not surgical candidates—with the biggest increase after 2015 (Figure 2). In fact, a more recent period of diagnosis was associated with an 80% increased likelihood of immunotherapy receipt (OR 1.80, 95% CI: 1.44–2.25).

Several factors may influence the availability and
### Table 3: Bivariable and multivariable analysis of factors associated with receipt of immunotherapy

<table>
<thead>
<tr>
<th>Variable</th>
<th>Bivariable analysis</th>
<th>Multivariable analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>≥65</td>
<td>0.57</td>
<td>0.48–0.67</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>0.74</td>
<td>0.62–0.89</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>1.12</td>
<td>0.88–1.42</td>
</tr>
<tr>
<td>Other</td>
<td>1.46</td>
<td>1.14–1.86</td>
</tr>
<tr>
<td><strong>Charlson-Deyo comorbidity index</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.75</td>
<td>0.61–0.92</td>
</tr>
<tr>
<td>2</td>
<td>0.85</td>
<td>0.63–1.15</td>
</tr>
<tr>
<td>3</td>
<td>0.70</td>
<td>0.52–0.94</td>
</tr>
<tr>
<td><strong>Period of diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004–2007</td>
<td>2.27</td>
<td>1.81–2.86</td>
</tr>
<tr>
<td>2008–2011</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>2012–2015</td>
<td>1.75</td>
<td>1.42–2.18</td>
</tr>
<tr>
<td><strong>Insurance status</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not insured</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Private insurance</td>
<td>1.96</td>
<td>1.27–3.02</td>
</tr>
<tr>
<td>Medicaid</td>
<td>1.21</td>
<td>0.74–1.97</td>
</tr>
<tr>
<td>Medicare</td>
<td>0.94</td>
<td>0.67–1.46</td>
</tr>
<tr>
<td><strong>Median income</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;$30,000</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>$30,000–$35,999</td>
<td>0.97</td>
<td>0.72–1.32</td>
</tr>
<tr>
<td>$36,000–$45,999</td>
<td>1.19</td>
<td>0.91–1.57</td>
</tr>
<tr>
<td>≥$46,000</td>
<td>1.41</td>
<td>1.09–1.81</td>
</tr>
<tr>
<td><strong>Facility type</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Community Cancer Program</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Comprehensive Community Cancer Program</td>
<td>0.86</td>
<td>0.60–1.25</td>
</tr>
<tr>
<td>Academic/Research Program</td>
<td>1.11</td>
<td>0.78–1.57</td>
</tr>
<tr>
<td>Integrated Network Cancer Program</td>
<td>0.82</td>
<td>0.53–1.27</td>
</tr>
<tr>
<td><strong>Residential setting</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rural</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>1.67</td>
<td>0.67–4.14</td>
</tr>
<tr>
<td>Metro</td>
<td>1.76</td>
<td>0.73–4.25</td>
</tr>
</tbody>
</table>
quality of cancer care. Structural factors such as health insurance or geographical distance, patient factors such as race, ethnicity, socioeconomic status, stage of disease, as well as other factors such as patient/physician preferences may all impact possible receipt of cancer therapies (28). Ward et al. suggested that although many factors contribute to treatment differences, unequal access to health care for financial or economic reasons may be the most important factor (29). To this point, in the current study, immunotherapy utilization for HBC varied among patients based on socioeconomic status. Specifically, after adjusting for competing risk factors such as tumor stage, higher income patients remained considerably more likely to receive immunotherapy compared with lower income individuals (OR 1.43, 95% CI: 1.11–1.87). Consistent with our findings, Al-Qurayshi et al. similarly noted that private insurance status and higher income level were associated with an increased likelihood or receiving immunotherapy among patients with advanced melanoma (30). Of note, while private insurance status was associated with a higher odds of receiving immunotherapy among HBC patients on unadjusted analyses, this association did not persist once income status was considered in the multivariate model as these covariates were likely colinear. While the cost related

<table>
<thead>
<tr>
<th>Variable</th>
<th>Bivariable analysis</th>
<th>Multivariable analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
</tr>
<tr>
<td><strong>Primary tumor</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gallbladder cancer</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>2.57</td>
<td>1.74–3.80</td>
</tr>
<tr>
<td>Intrahepatic cholangiocarcinoma</td>
<td>2.45</td>
<td>1.58–3.79</td>
</tr>
<tr>
<td>Extrahepatic bile duct cancer</td>
<td>1.78</td>
<td>1.15–2.74</td>
</tr>
<tr>
<td><strong>Histological confirmation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1.44</td>
<td>1.19–1.75</td>
</tr>
<tr>
<td><strong>Grade</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Mod</td>
<td>1.37</td>
<td>1.00–1.88</td>
</tr>
<tr>
<td>Poor</td>
<td>1.20</td>
<td>0.86–1.69</td>
</tr>
<tr>
<td>Anaplastic</td>
<td>0.88</td>
<td>0.28–2.82</td>
</tr>
<tr>
<td><strong>AJCC clinical stage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>1.34</td>
<td>0.97–1.86</td>
</tr>
<tr>
<td>III</td>
<td>2.37</td>
<td>1.78–3.15</td>
</tr>
<tr>
<td>IV</td>
<td>2.90</td>
<td>2.23–3.78</td>
</tr>
<tr>
<td><strong>Surgery</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0.75</td>
<td>0.63–0.90</td>
</tr>
<tr>
<td><strong>Chemotherapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>3.42</td>
<td>2.87–4.09</td>
</tr>
<tr>
<td><strong>Radiation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1.99</td>
<td>1.64–2.43</td>
</tr>
</tbody>
</table>

Well, well differentiated; mod, moderately differentiated; poor, poorly differentiated.
to immunotherapy receipt among HBC patients could not be estimated in the current study, other studies have reported that the cost of immune checkpoint inhibitors for melanoma and NSCLC range from $64,000–$145,000 per person per year (31). A separate study noted a cost of $93,000 per treatment for an FDA approved cancer vaccine therapy to treat prostate cancer (32). Given the high cost of immunotherapy, the health care system and insurance plans will need to take into consideration the ramifications of this therapy relative to the potential financial impact on patients.

Another interesting aspect of the current study was the characterization of the timing of immunotherapy among surgical and non-surgical patients. For most patients with advanced cancer, multi-modality therapy is required and the timing of therapy can vary depending on a number of factors. While immunotherapy can be administered as an adjuvant therapy or as palliative therapy in the case of recurrence among surgical patients, immunotherapy can be used either as a first line or second line therapy for those patients with more advanced unresectable disease (33). Data from the current study demonstrated that immunotherapy was typically delivered later in the HBC treatment course. Specifically, among surgical patients who received immunotherapy, it was delivered on average 40–50 days following surgery (Figure 3A). In contrast, among patients with more advanced disease who did not undergo surgical resection, cytotoxic chemotherapy was more commonly utilized after the diagnosis of HBC with immunotherapy being administered later in the clinical course (Figure 3A,B). Not surprisingly, these data suggest that immunotherapy was largely being used as second or third line agents in most patients with advanced disease after standard chemotherapy likely failed to control disease progression.

Several limitations should be considered when interpreting data in the current study. While the NCDB is a large administrative database, some of the data elements are limited including the lack of information on the possible contraindications for immunotherapy such as renal dysfunction, performance status, and patient preference. Similar to previous studies (34-38), the current study included patients with resectable tumors who had favorable prognostic features (i.e., small tumors, negative surgical margins), some of whom may not have traditionally been considered for neoadjuvant or adjuvant systemic therapy. In addition, data on the specific types of immunotherapy regimens, the number of cycles, as well as any associated toxicities among those patients receiving immunotherapy were not available. As data from NCDB were also only available until 2015, we were unable to analyze data for more recent years.

Conclusions

The overall utilization of immunotherapy in the US among patients with HBC was very low, yet has increased over the last several years examined. Certain socioeconomic factors were associated with an increased likely of receiving immunotherapy, which may suggest disparities in access or enrollment of patients with lower socioeconomic status. As the role of immunotherapy for HBC continues to expand, a better understanding of the overall utilization patterns, as well as the factors associated with receipt of immunotherapy, will be needed.

Acknowledgments

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was approved by the institutional research review committee.

References


### Table S1 International Classification of Disease for Oncology (ICD-O-3) codes, Diagnoses and Procedure Codes to Identify Cases

<table>
<thead>
<tr>
<th>Primary tumor</th>
<th>ICD-O-3 code</th>
<th>Topographical codes</th>
<th>Morphological codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular carcinoma</td>
<td>C22.0</td>
<td>8170/3, 8171/3, 8180/3</td>
<td></td>
</tr>
<tr>
<td>Intrahepatic cholangiocarcinoma</td>
<td>C22.0 or C22.1</td>
<td>8970/3, 8020/3, 8160/3, 8960/3, 8963/3</td>
<td></td>
</tr>
<tr>
<td>Gallbladder cancer</td>
<td>C23.9</td>
<td>8140/3, 8144/3, 8310/3, 8480/3, 8490/3, 8560/3, 8070/3, 8020/3</td>
<td></td>
</tr>
<tr>
<td>Extrahepatic bile duct cancer</td>
<td>C24.0, C24.1, C24.8, C24.9</td>
<td>8140/3, 8144/3, 8310/3, 8480/3, 8490/3, 8560/3, 8070/3, 8020/3</td>
<td></td>
</tr>
</tbody>
</table>